How Do You Know If You Have Fatty Liver Disease?

Fatty liver disease rarely announces itself with obvious symptoms. Most people learn they have it only after a routine blood test shows elevated liver enzymes, or an imaging scan done for an unrelated reason reveals unexpected fat in the liver. The condition has earned the label “silent liver disease” for good reason, and understanding the various ways it gets detected, from simple blood work to specialized imaging, matters because early-stage fat buildup is reversible while advanced scarring is not.

Why Most People Feel Nothing at All

The hallmark of fatty liver disease in its early stages is the absence of symptoms. When fat accumulates in liver cells without triggering significant inflammation, the condition is classified as simple steatosis, and it tends to follow a benign course.¹ You can carry excess liver fat for years or even decades without any outward sign. This is partly why experts in pediatric liver disease have described the condition as a “silent epidemic” among children and adolescents, where metabolic risk factors are rising but overt symptoms remain rare.²

When symptoms do eventually surface, they tend to be vague and easy to attribute to something else. In one study examining the clinical presentations of patients with confirmed fatty liver disease, the most common complaints were upper abdominal pain, fatigue, thirst, and anxiety.³ None of those scream “liver problem” to the average person, which is precisely the challenge. If the disease progresses all the way to cirrhosis and the liver begins to fail, the signs become harder to miss: fluid buildup in the abdomen, confusion from toxins the liver can no longer clear, and bleeding from swollen veins in the esophagus.⁴ But those are late-stage complications. The whole point of detection is catching things long before that.

Blood Tests as the First Clue

For many people, the first hint of fatty liver disease comes from a routine metabolic panel. Two liver enzymes, ALT and AST, are commonly measured in standard blood work. When these enzymes are elevated, it means liver cells are being damaged and are leaking their contents into the bloodstream. Fatty liver disease, particularly the inflammatory form, is one of the most common causes of elevated ALT and AST seen in primary care, along with alcohol use, medications, and viral hepatitis.⁵

Here is an important catch, though: your liver enzymes can be completely normal even when you have fatty liver. Simple steatosis without much inflammation often does not push ALT or AST above the lab’s reference range. So normal blood work does not rule it out. Conversely, elevated enzymes do not automatically mean fatty liver. Your doctor will typically want to exclude viral hepatitis, alcohol-related damage, and medication side effects before settling on a diagnosis. The blood test is a starting point, not a destination.

Ultrasound Is Usually the First Imaging Step

If your blood work or risk profile raises suspicion, an abdominal ultrasound is the standard next move. It is cheap, widely available, painless, and involves no radiation. The ultrasound operator looks for a characteristic bright, echogenic appearance of the liver, which indicates fat infiltration. A meta-analysis pooling results from 34 studies found that ultrasound detected moderate-to-severe fatty liver with roughly 85% sensitivity and 94% specificity.⁶ In practical terms, it is good at catching cases where fat involves a substantial portion of the liver, but it can miss milder cases.

Ultrasound also has a significant limitation: it cannot tell you how much scarring (fibrosis) has developed. When fat involves more than about a third of the liver and clinical risk factors are present, ultrasound can reliably confirm fatty liver, but it cannot replace a biopsy for staging the degree of fibrosis.⁷ So a positive ultrasound tells you that you have fat in the liver. It does not tell you how worried to be about it.

FibroScan and Elastography

To answer the question ultrasound leaves open, doctors increasingly use a device called FibroScan, which measures liver stiffness using a technique called transient elastography. A stiffer liver suggests more fibrosis. The device can also estimate how much fat is present using something called the controlled attenuation parameter, making it a two-in-one tool that assesses both fat and scarring in a single exam.⁸ The exam takes about ten minutes, is done at bedside, and feels like an ultrasound probe pressing firmly against your right side.

FibroScan has demonstrated good accuracy in quantifying both liver fat and fibrosis in people with fatty liver disease.⁹ It is not perfect. Results can be thrown off by obesity, active inflammation, or eating before the test. But for the vast majority of patients, it provides a reliable, noninvasive snapshot of where things stand, without needing a needle in the liver.

MRI for the Most Precise Measurement

When researchers need the most accurate noninvasive measurement of liver fat, or when results from other tests are ambiguous, MRI offers a technique called proton density fat fraction (MRI-PDFF). This specialized MRI scan produces a precise percentage of liver fat content and is increasingly used as a benchmark in clinical trials testing new treatments for fatty liver disease.¹⁰

In a study comparing MRI-PDFF against biopsy results, the two methods correlated strongly, with a correlation coefficient of 0.82 between MRI readings and the actual percentage of fat-laden liver cells seen under the microscope.¹¹ The downside is cost and availability. An MRI-PDFF scan is considerably more expensive than ultrasound or FibroScan, and not every imaging center offers it. For most patients in routine clinical care, it is reserved for cases where other methods have given conflicting results or when tracking treatment response with high precision is needed.

When a Liver Biopsy Is Still Necessary

Despite all the noninvasive options, a liver biopsy remains the reference standard for distinguishing simple fatty liver from the more concerning inflammatory form (called steatohepatitis), and for precisely staging fibrosis.¹² It is the only test that can show, under a microscope, exactly what kind of damage is happening at the cellular level, including the degree of inflammation and the pattern and extent of scarring.¹³

That said, biopsy is invasive. It involves inserting a needle through the skin into the liver to extract a small tissue sample, which carries a small risk of pain, bleeding, and very rarely, more serious complications. It also samples only a tiny sliver of a large organ, so sampling error is a recognized limitation. Because of these downsides, researchers are actively working to develop blood-based biomarkers that could eventually replace biopsy. A large multicenter study evaluated 17 different noninvasive biomarkers head-to-head in a single group of patients, with the goal of finding tests that can reliably detect steatohepatitis and significant fibrosis without a needle.¹⁴ The field is getting closer, but biopsy has not been fully replaced yet.

Simple Risk Scores Your Doctor Can Calculate

One of the most practical tools for fatty liver disease does not require any imaging at all. The FIB-4 score is a simple formula that combines your age, platelet count, and ALT and AST levels to estimate whether you have significant liver fibrosis. It is free, uses information already available from routine blood tests, and can be calculated automatically by electronic health record systems. In a study of over 3,400 patients screened in primary care, about a quarter had FIB-4 scores suggesting at least intermediate risk of fibrosis.¹⁵

High-risk FIB-4 scores have been strongly associated with serious liver outcomes in patients both with and without previously known liver disease, suggesting the score can catch silently advancing fibrosis that would otherwise go unnoticed.¹⁶ A care pathway endorsed by multiple liver disease organizations recommends that all at-risk patients, including those with type 2 diabetes, those with multiple metabolic risk factors, and those with incidental findings of fatty liver or elevated enzymes, should undergo noninvasive fibrosis testing using scores like FIB-4 as an initial screening step.¹⁷ The 2019 American Diabetes Association guidelines specifically called for clinicians to screen all patients with type 2 diabetes who have liver fat or abnormal liver enzymes.¹⁸

When a FIB-4 score comes back in the intermediate or high range, the typical next step is a second-line test. In some settings, the Enhanced Liver Fibrosis (ELF) blood test is used to confirm or refute the initial signal before referring a patient to a specialist. One implementation study found that incorporating FIB-4 screening followed by the ELF test led to better-targeted specialist referrals, with a significant increase in the proportion of referred patients who actually had advanced fibrosis.¹⁹

Self-Assessment Tools That Skip the Lab

Researchers have also developed screening scores that do not require any lab results at all. One validated self-assessment score uses seven basic risk factors, things you already know about yourself like age, waist circumference, and whether you have diabetes, to estimate your likelihood of having fatty liver. In the development study, this simple score performed well, achieving an area under the curve of 0.82 for men and 0.88 for women, with only a minimal loss of accuracy compared to scores that included blood work.²⁰ A score like this cannot diagnose fatty liver on its own, but it can help you and your doctor decide whether further testing is warranted.

A newer tool called the LiverRisk score takes a somewhat different approach, predicting not just liver fibrosis but also liver-related and diabetes-related mortality in the general population. It outperformed conventional scoring systems with an area under the curve of 0.76 for detecting clinically significant advanced chronic liver disease.²¹ These tools are still relatively new, and none are yet standard in most primary care offices. But they point toward a future where liver risk assessment becomes as routine as checking your cholesterol.

Incidental Findings on Scans Done for Other Reasons

A surprisingly common way people discover fatty liver is through imaging that was ordered for something else entirely. You go in for a CT scan to evaluate abdominal pain, kidney stones, or another complaint, and the radiologist notes that your liver looks fatty. This “opportunistic screening” is becoming recognized as a legitimate detection pathway. One study of 450 patients who underwent abdominal CT scans for non-liver reasons found that about a quarter met standard imaging criteria for fatty liver, but only a small fraction of those findings had been formally reported by the radiologist, and 85% of family physicians were unaware of the finding in their patients’ charts.²²

Researchers have argued that systematically flagging incidental liver fat on routine CT and ultrasound scans is feasible and produces substantial yield, catching patients with clinically meaningful fatty liver disease who would otherwise slip through the cracks.²³ The finding of liver fat on imaging done for non-liver conditions may represent an underused avenue for identifying people with metabolic fatty liver disease who need follow-up.²⁴ If a radiologist mentions “hepatic steatosis” or “fatty liver” on your scan report, it is worth bringing up with your primary care doctor even if it was not the reason for the scan.

The Name Change You Might Encounter

If you have been reading about fatty liver disease recently, you may have noticed new terminology. What was called nonalcoholic fatty liver disease (NAFLD) has been officially renamed metabolic dysfunction-associated steatotic liver disease, or MASLD. The change happened through an international consensus process and was motivated by a few problems with the old name: “nonalcoholic” defined the disease by what it was not rather than what caused it, and it carried a stigmatizing implication about alcohol use.²⁵

Under the new criteria, a MASLD diagnosis requires the presence of liver fat plus at least one cardiometabolic risk factor, such as overweight, elevated blood sugar, high blood pressure, or abnormal cholesterol. This shift does not change how the disease is detected; all the same tests still apply. But it does mean that if your doctor mentions MASLD, they are talking about the same condition that used to be called NAFLD, just with a name that better reflects the metabolic drivers behind it.

You Do Not Have to Be Overweight

One of the most persistent misconceptions about fatty liver disease is that it only affects people who are visibly overweight. In reality, a meaningful proportion of people with fatty liver have a normal body mass index. This is sometimes called “lean NAFLD” or “lean MASLD.” These individuals share some of the same metabolic abnormalities as those with obesity-related fatty liver, including insulin resistance and abnormal cholesterol, but they also show differences in genetic predisposition and body composition.²⁶

The American Gastroenterological Association published a clinical practice update specifically addressing lean fatty liver, defining it as NAFLD in individuals with a BMI below 25 (or below 23 for people of Asian descent). The guidance also notes that in lean patients, doctors should be especially careful to rule out other causes of liver fat, including certain medications like methotrexate, amiodarone, and tamoxifen, as well as rarer conditions such as lipodystrophy.²⁷ The practical takeaway is that you should not assume your liver is fine just because your weight is in a healthy range. If you have metabolic risk factors or unexplained enzyme elevations, fatty liver should still be on the list of possibilities.

Fatty Liver in Children and Adolescents

Fatty liver disease is no longer just an adult concern. With rising rates of childhood obesity, the condition is increasingly diagnosed in children, and it presents unique challenges in younger patients. The European Society for Paediatric Gastroenterology, Hepatology and Nutrition recommends suspecting fatty liver in all overweight or obese children over age three who have an increased waist circumference, particularly if there is a family history of the condition. The typical presentation, however, occurs in children aged ten and older. The recommended first step is an abdominal ultrasound combined with liver function tests, followed by exclusion of other liver diseases.²⁸

A tricky aspect of pediatric screening is that both ultrasound and liver enzyme tests can appear normal at a single assessment even when fatty liver is present. The ESPGHAN position paper specifically advises ongoing monitoring of overweight and obese children even after initial tests come back clean. Liver biopsy, while still the gold standard, is used more sparingly in children due to practical and ethical considerations, typically reserved for ruling out other treatable diseases or when advanced liver disease is suspected clinically.²⁹

Telling Fatty Liver Apart from Alcohol-Related Liver Disease

If you drink alcohol regularly and are also overweight or have metabolic risk factors, figuring out whether your liver damage is driven by fat accumulation, alcohol, or both can be genuinely difficult. The two conditions can look similar on imaging and even under the microscope. Researchers have developed clinical indices to help distinguish them. One such tool, the Alcoholic Liver Disease/NAFLD Index (ANI), uses a combination of clinical variables to classify patients, and in validation studies it achieved 84% sensitivity and 97% specificity in separating alcohol-related liver disease from metabolic fatty liver disease.³⁰ In practice, your doctor will also rely heavily on an honest conversation about your drinking habits, since the diagnostic tests alone cannot always draw a clean line between the two.

The Spectrum from Fat to Fibrosis

Understanding fatty liver disease as a spectrum helps explain why detection matters even when you feel fine. The condition ranges from simple fat accumulation, which is considered benign, through steatohepatitis, where active inflammation and cell injury are occurring, to fibrosis and eventually cirrhosis.³¹ Most people with cirrhosis remain asymptomatic until the disease decompensates, at which point serious complications emerge.⁴

The encouraging news is that liver fat and even early fibrosis can improve with weight loss, dietary changes, and exercise. The discouraging news is that by the time symptoms force you to see a doctor, the window for easy reversal may have already closed. This is why the push toward routine screening in high-risk groups is gaining momentum. Fatty liver disease is common enough and serious enough in its advanced stages that waiting for symptoms is a losing strategy.

Emerging Research on Gut Microbiome Signatures

One area of active investigation is whether the bacteria living in your gut could serve as a diagnostic signal. An integrative study across multiple patient groups found that gut microbiome analysis could distinguish advanced liver diseases from healthy controls with reasonable accuracy, but early-stage conditions like fatty liver and hepatitis showed weak separability, reflecting the biological variability of early disease.³² In other words, a stool test for fatty liver is not ready for clinical use. But as researchers identify stage-specific microbial patterns, microbiome-based diagnostics could eventually fill a gap that blood tests and imaging leave open, particularly in distinguishing who among the millions with liver fat is actually on a path toward serious disease.